Among the new drugs with specific molecular targets sorafenib was shown to be effective in renal cell carcinoma and hepatocarcinoma, I through the inhibition of ERK1/2 pathway [17,18]. This evidence concerns the gene MAPK3 and renal cell carcinoma.